Multiple Sclerosis | Emerging Therapies | Ocrevus in PP-MS (Wave 2) | US – 2017
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, many questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch-tracking series examines how the perception and performance of Ocrevus evolves through Year 1 with an MS prescriber base that has struggled to treat PP-MS.
What you will learn in this content
- What is the awareness of, familiarity with, and perceptions related to Ocrevus among U.S. neurologists?
- For which patients are neurologists prescribing Ocrevus, what are the reasons for prescribing, and how satisfied are they with Ocrevus?
- What promotional messages and activities are Genentech/Roche employing in support of the Ocrevus launch in PP-MS?
- How does the trial and adoption of Ocrevus in PP-MS compare with Ocrevus and other recent product launches in the saturated relapsing MS market? How do adopters and nonadopters in PP-MS compare across key metrics?
Product description
Launch Tracking: Ocrevus in Primary Progressive Multiple Sclerosis (US) is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
